Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
contact us
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
Home
Indication Area
NRT
Pharma
Partners
Team
Newsroom
CONTACT US
Have a Project in Mind? Say Hi!
+1 800 123 456 789
+1 800 123 654 987
Mon - Sun: 10am - 10pm
27 Division St, New York,
NY 10002, USA
grido@mail.com
Home
Posts Tagged "Press Release"
Press Release TAG
Tag:
Press Release
April 10, 2025
PR Neweswire
BY
admin
Qnovia, Inc. Announces Leadership Transition and Strategic Appointments to Support UK Commercialization Strategy
January 7, 2025
PR Neweswire
BY
admin
Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
December 10, 2024
PR Neweswire
BY
admin
Qnovia, Inc. Raises $16 Million in Series B Financing to Advance Lead Asset RespiRx™ Nicotine Inhaler as a Prescription Smoking Cessation Therapy
October 21, 2024
PR Neweswire
BY
admin
Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options
October 1, 2024
PR Neweswire
BY
admin
Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
April 9, 2024
Business Wire
BY
admin
Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board
November 30, 2023
Business Wire
BY
admin
Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy
October 19, 2023
Business Wire
BY
admin
Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases
April 4, 2023
Business Wire
BY
admin
Qnovia, Inc. Announces Former Director of FDA’s Center for Tobacco Products, Mitch Zeller, as Policy and Regulatory Strategy Advisor
November 8, 2022
Business Wire
BY
admin
Qnovia to Pursue UK Approval for Lead Asset QN-01 in Nicotine Replacement Therapy
1
2
#side-panel.side-panel {width: 500px;}#side-panel.side-panel .side-panel_sidebar {padding: 70px 0px 50px 60px;background-color: #FFFFFF;}
Qnovia